# Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

> **NCT00002943** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 11 (actual)

## Conditions studied

- Extragonadal Germ Cell Tumor
- Ovarian Cancer
- Testicular Germ Cell Tumor
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** carboplatin
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **PROCEDURE:** autologous bone marrow transplantation

## Key facts

- **NCT ID:** NCT00002943
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-02
- **Primary completion:** 2003-10
- **Final completion:** 2007-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002943, "Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*